Valuation and Other Thoughts
11/17/2020: BMY's P/E is a bit off due to one time charges and thus doesn't offer much insight. Overall, it is a cheap stock with solid dividend. Its recent acquisition of Celgene upped its over debt, but also added a nice revenue bump.
Recommendation: Buy, as a Stable dividend pick (also run covered call to collect extra premium and improve overall cash flow)